The incidence of neuroendocrine tumors is increasing, necessitating the need for more post-operative medical strategies. Available therapies and promising agents are discussed in this article.

Five-year View New biomarkers for early diagnosis and recurrence of disease will be developed. Molecular imaging will increase in the management of NETs. 68 Ga-DOTA octreotate will probably be ...

In the article that accompanies this editorial, Babiker et al 12 present the data that tumor-treating fields (TTFs) combined with gemcitabine plus nab-paclitaxel improved median overall survival ...

Beta Bionics is a commercial-stage medical technology company dedicated to simplifying diabetes management and improving outcomes for people requiring insulin therapy. By leveraging advanced adaptive ...

This study is to find out more about the drug everolimus (also known Afinitor) as a treatment for neuroendocrine tumours of the pancreas.

By leveraging advanced adaptive algorithms, Beta Bionics has developed the iLet ® Bionic Pancreas-the first FDA-cleared insulin delivery device with a fully autonomous insulin dosing algorithm.

Fibroid Tumors: What Every Woman Must Know Diagnosed with fibroids? Three experts help WebMD explore your treatment options.

Beta Bionics plans to integrate its iLet Bionic Pancreas with Abbott's upcoming dual glucose-ketone sensor for enhanced diabetes management.

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors – A regulatory decision by the ...

Figure 2: Pelvic MRI scans of a 62-year-old white male with rectal neuroendocrine carcinoma, taken at the time of diagnosis. The rectal tumor is displayed on all scans.